Akebia Therapeutics (AKBA) Revenue & Revenue Breakdown
Akebia Therapeutics Revenue Highlights
Latest Revenue (Y)
$236.20M
Latest Revenue (Q)
$58.77M
Main Segment (Y)
License Collaboration And Other Revenue
Main Geography (Y)
Product
Akebia Therapeutics Revenue by Period
Akebia Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $236.20M | 47.46% |
| 2024-12-31 | $160.18M | -17.70% |
| 2023-12-31 | $194.62M | -33.46% |
| 2022-12-31 | $292.48M | 38.19% |
| 2021-12-31 | $211.65M | -28.17% |
| 2020-12-31 | $294.64M | -12.05% |
| 2019-12-31 | $335.00M | 61.26% |
| 2018-12-31 | $207.74M | 16.72% |
| 2017-12-31 | $177.98M | 11495.05% |
| 2016-12-31 | $1.53M | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | - |
Akebia Therapeutics generated $236.20M in revenue during NA 2025, up 47.46% compared to the previous quarter, and up 80.16% compared to the same period a year ago.
Akebia Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $58.77M | -5.93% |
| 2025-06-30 | $62.47M | 8.96% |
| 2025-03-31 | $57.34M | 23.31% |
| 2024-12-31 | $46.50M | 24.23% |
| 2024-09-30 | $37.43M | -14.25% |
| 2024-06-30 | $43.65M | 33.86% |
| 2024-03-31 | $32.61M | -41.98% |
| 2023-12-31 | $56.20M | 33.65% |
| 2023-09-30 | $42.05M | -25.42% |
| 2023-06-30 | $56.38M | 40.92% |
| 2023-03-31 | $40.01M | -27.50% |
| 2022-12-31 | $55.18M | 12.70% |
| 2022-09-30 | $48.96M | -61.37% |
| 2022-06-30 | $126.76M | 105.45% |
| 2022-03-31 | $61.70M | 3.51% |
| 2021-12-31 | $59.60M | 22.25% |
| 2021-09-30 | $48.76M | -7.86% |
| 2021-06-30 | $52.91M | 1.16% |
| 2021-03-31 | $52.30M | -7.75% |
| 2020-12-31 | $56.70M | -5.48% |
| 2020-09-30 | $59.99M | -33.45% |
| 2020-06-30 | $90.14M | 1.88% |
| 2020-03-31 | $88.48M | 27.21% |
| 2019-12-31 | $69.56M | -24.38% |
| 2019-09-30 | $91.98M | -8.76% |
| 2019-06-30 | $100.80M | 38.72% |
| 2019-03-31 | $72.67M | 21.41% |
| 2018-12-31 | $59.85M | 12.57% |
| 2018-09-30 | $53.17M | 8.97% |
| 2018-06-30 | $48.79M | 6.23% |
| 2018-03-31 | $45.93M | -47.40% |
| 2017-12-31 | $87.32M | 111.51% |
| 2017-09-30 | $41.28M | 44.75% |
| 2017-06-30 | $28.52M | 36.69% |
| 2017-03-31 | $20.86M | 1259.28% |
| 2016-12-31 | $1.53M | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | - |
Akebia Therapeutics generated $58.77M in revenue during Q3 2025, up -5.93% compared to the previous quarter, and up 134.64% compared to the same period a year ago.
Akebia Therapeutics Revenue Breakdown
Akebia Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| License Collaboration And Other Revenue | $8.86M | $8.00M | $24.32M | $115.53M | $71.36M |
| Supply Agreement | $300.00K | - | - | - | - |
| License Collaboration And Other Revenue, Royalties | $100.00K | - | - | - | - |
| Product | - | $152.18M | $170.30M | $177.07M | $142.22M |
Akebia Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: License Collaboration And Other Revenue (95.68%), Supply Agreement (3.24%), and License Collaboration And Other Revenue, Royalties (1.08%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License Collaboration And Other Revenue | $3.33M | $1.98M | $2.01M | $1.54M | $4.57M | $1.84M | $1.60M | $4.89M | $14.13M | $5.30M | $5.50M | $6.72M | $83.06M | $20.25M | $17.51M | $12.00M | $19.95M | $21.90M | $22.09M | $25.60M |
| Product | - | $56.79M | $60.46M | $55.79M | $85.58M | $35.59M | $31.01M | $93.23M | $42.24M | $34.83M | $49.68M | $42.24M | $43.70M | $41.45M | $42.10M | $36.75M | $32.96M | $30.41M | $34.60M | $34.39M |
Akebia Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: License Collaboration And Other Revenue (100.00%).
Akebia Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| License Collaboration And Other Revenue | $115.53M | $71.36M | $166.41M | $223.88M | $200.47M |
| Product | $177.07M | $142.22M | $128.90M | $111.12M | - |
Akebia Therapeutics's latest annual revenue breakdown by geography, as of Dec 22: Product (60.51%), and License Collaboration And Other Revenue (39.49%).
Quarterly Revenue by Country
| Country | Mar 23 | Jun 20 |
|---|---|---|
| License Collaboration And Other Revenue | $5.30M | - |
| Product | $34.83M | - |
| Non-US | - | $65.00M |
Akebia Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: Product (86.79%), and License Collaboration And Other Revenue (13.21%).
Akebia Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RIGL | Rigel Pharmaceuticals | $294.28M | $69.46M |
| AKBA | Akebia Therapeutics | $236.20M | $58.77M |
| GOSS | Gossamer Bio | $114.70M | $13.29M |
| ZVRA | Zevra Therapeutics | $106.47M | $26.06M |
| PRTA | Prothena | $9.68M | $2.42M |
| CRVS | Corvus Pharmaceuticals | - | - |
| CMPX | Compass Therapeutics | - | - |
| VTYX | Ventyx Biosciences | - | - |
| FDMT | 4D Molecular Therapeutics | - | - |
| KALV | KalVista Pharmaceuticals | - | $13.69M |
| OLMA | Olema Pharmaceuticals | - | - |